Evidence map›Paper›PMID 42326163›Full record

ArticleCureus2026

Tuberculous Miliary Disease Following Intravesical Bacillus Calmette-Guérin Therapy for Urothelial Carcinoma of the Bladder: A Case Report.

Achraf Benamou, Anouar El Moudane, Ali Barki

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Achraf BenamouUrology, Mohammed VI University Hospital, Oujda, MAR.
Anouar El MoudaneUrology, Mohammed VI University Hospital, Oujda, MAR.
Ali BarkiUrology, Mohammed VI University Hospital, Oujda, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the standard adjuvant treatment for non-muscle-invasive bladder cancer. Although highly effective, BCG therapy may be associated with rare but potentially severe systemic complications. We report the case of a 52-year-old man treated with intravesical BCG for carcinoma in situ of the bladder who subsequently developed miliary tuberculosis. This case shows that general complications of intravesical BCG therapy are becoming increasingly frequent and should be used with caution while respecting international recommendations.

Indexed as

bladder cancerinfectionintravesical bcg therapymiliary tuberculosissystemic complications

Identifiers

PMID42326163
PMCPMC13280610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.